Sagimet Biosciences Inc.
SGMT evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $676.3M
What it means
What to watch
Prepared research question
What matters most for SGMT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SGMT
Sagimet Biosciences Inc. (SGMT) is a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, with a lead program in denifanstat for acne and MASH.
Key risk: Single-asset dependency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$676.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 7 clinical trials for Sagimet Biosciences Inc..
Sagimet Biosciences Inc. (SGMT) is a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, with a lead program in denifanstat for acne and MASH.
- Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund operations through 2028 [news].
- Phase 3 clinical trial of denifanstat in moderate to severe acne patients on track to initiate in second half of 2026, with FDA IND clearance received [news].
- Denifanstat met all primary and multiple secondary endpoints in the Phase 2b FASCINATE-2 trial in MASH patients [sec_mda].
- Completed a $175.0 million equity financing in April 2026 [sec_mda].
- First-in-human Phase 1 trial of FASN inhibitor TVB-3567 for acne ongoing [news].
What works
- Denifanstat has demonstrated positive Phase 2b data in MASH, meeting all primary and multiple secondary endpoints [sec_mda].
- The company has a strong cash position of $257.6 million as of June 30, 2026, providing runway through 2028 [news].
- FDA has cleared the IND for the Phase 3 acne trial, de-risking the regulatory pathway [news].
- The combination of denifanstat and resmetirom was well-tolerated with no safety signals in a Phase 1 PK trial [sec].
What to weigh
- Net loss widened to $14.0 million in the quarter ended June 30, 2026, with R&D expenses rising [news].
- The company is reliant on a single lead asset, denifanstat, for near-term catalysts [news].
- No sales have been made under the $75.0 million ATM offering established in August 2025 [sec_mda].
- The Phase 3 acne trial has not yet initiated enrollment as of August 2026, with patient screening expected to begin in October 2026 [news].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026”
News · August 11, 2026
Denifanstat Phase 2b MASH trial results
“Denifanstat met all primary and multiple secondary endpoints in the Phase 2b FASCINATE-2 clinical trial”
SEC MD&A · May 12, 2026
Equity financing in April 2026
“On April 28, 2026, we completed an underwritten offering whereby we sold 29,166,700 shares of our Series A common stock at a price of $6.00 per share for gross proceeds of approximately $175.0 million”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2021-04-30 · First-in-human study of TVB-2640 alone and with a taxane in advanced tumors — Trial readout showed a 42% disease control rate with monotherapy and 11% partial response rate in combination with paclitaxel.
Risks & what to watch (4)›
Key risks
- Single-asset dependency — Near-term catalysts are anchored to denifanstat; failure in Phase 3 acne trial would be a major setback [news].
- Rising R&D costs — R&D expense rose to $11.5M in Q2 2026 from $7.2M a year earlier, contributing to a widened net loss [news].
- ATM offering unsold — No shares sold under the $75M ATM offering established in August 2025 as of May 2026 [sec_mda].
- Phase 3 trial execution risk — Enrollment not yet initiated as of August 2026; first patient expected after October 2026 [news].
What to watch
- Initiation of the Phase 3 AURORA acne trial enrollment, expected Q4 2026 [news].
- Data readout from the Phase 3 denifanstat acne trial, expected to be funded through 2028 [news].
- Progress of the denifanstat and resmetirom combination program, anticipated to be Phase 2-ready in H2 2026 [sec_mda].
- First-in-human Phase 1 data for TVB-3567 in acne [news].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Sagimet Biosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sagimet Biosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.03 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 5 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
87
Total value held
$68.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,098,919 | $5.7M |
| woodline partners lp | 1,000,943 | $5.2M |
| marshall wace, llp | 966,253 | $5.0M |
| baker bros. advisors lp | 952,996 | $5.0M |
| affinity asset advisors, llc | 868,020 | $4.5M |
| millennium management llc | 862,303 | $4.5M |
| blackrock, inc. | 799,943 | $4.2M |
| hhlr advisors, ltd. | 724,800 | $3.8M |
| renaissance technologies llc | 625,469 | $3.3M |
| d. e. shaw & co., inc. | 411,570 | $2.2M |
Showing top 10 of 87 institutional holders of Sagimet Biosciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 12.1%
- Days to cover
- 9.3
- Shares short
- 3,598,600
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SGMT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Sagimet Biosciences Inc.?
Sagimet Biosciences Inc. (SGMT) is a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, with a lead program in denifanstat for acne and MASH.
Who is the CEO of Sagimet Biosciences Inc.?
Mr. David A. Happel is the chief executive officer of Sagimet Biosciences Inc. (SGMT).
Where is Sagimet Biosciences Inc. headquartered?
Sagimet Biosciences Inc. (SGMT) is headquartered in San Mateo, CA, United States.
What therapeutic areas does Sagimet Biosciences Inc. focus on?
Sagimet Biosciences Inc. develops therapies across Oncology, Infectious Disease, Metabolic, Dermatology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.